Cyclopeptide Utilizing Patents (Class 514/3.6)
-
Patent number: 8415307Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.Type: GrantFiled: June 23, 2011Date of Patent: April 9, 2013Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
-
Publication number: 20130059774Abstract: Novel compositions and methods of reducing microbial resistance to antimicrobial agents and treating infections are disclosed. In particular, compositions and methods of inhibiting efflux pump activity, treating infection and methods of enhancing antimicrobial activity of antimicrobial agents are provided.Type: ApplicationFiled: April 1, 2010Publication date: March 7, 2013Inventors: Mahesh Vithalbhai Patel, Sachin Subhash Bhagwat, Mohammad Alam Jafri
-
Publication number: 20130028940Abstract: The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. Said compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. Said compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product.Type: ApplicationFiled: June 25, 2012Publication date: January 31, 2013Applicant: SANDOZ AGInventors: Christian Welz, Gottfried Stubauer, Andreas Schmarda, Herwig Jennewein, Ingolf Macher, Johannes Ludescher
-
Publication number: 20130023462Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.Type: ApplicationFiled: September 27, 2012Publication date: January 24, 2013Inventors: Sachin Mittal, Hossain Jahansouz, Sutthilug Sotthivirat
-
Patent number: 8324154Abstract: The present invention relates to cyclic cationic peptides and their use in the treatment of microbial infections.Type: GrantFiled: December 21, 2006Date of Patent: December 4, 2012Assignee: Novabiotics, Ltd.Inventor: Deborah O'Neil
-
Patent number: 8309515Abstract: The present invention relates to micelle-forming poly(ethylene oxide)-block-poly(ester) block copolymers having reactive groups on the polyester block therein. The biodegradability of these copolymers and their biocompatibilities with a large number of bioactive agents make them suitable as carriers for various bioactive agents. The bioactive agents, such as DNA, RNA, oligonucleotide, protein, peptide, drug and the like, can be coupled to the reactive groups on the polyester block of the copolymer.Type: GrantFiled: March 21, 2007Date of Patent: November 13, 2012Assignee: The Governors of the University of AlbertaInventors: Afsaneh Lavasanifar, Abdullah Mahmud
-
Publication number: 20120276182Abstract: The present invention relates to methods for treating and completely curing fungal, yeast, and/or mold infections in human subjects comprising topically administering to a human subject in need thereof an antifungal nanoemulsion composition.Type: ApplicationFiled: July 9, 2012Publication date: November 1, 2012Inventors: James R. Baker, JR., Mary R. Flack, Susan M. Ciotti, Joyce A. Sutcliffe
-
Publication number: 20120231996Abstract: The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.Type: ApplicationFiled: June 9, 2011Publication date: September 13, 2012Inventors: R. Scott Lokey, Laura A. Schuresko
-
Publication number: 20120207762Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Lakshmy Nair, Reagan Miller, Barrett E. Rabinow
-
Patent number: 8232245Abstract: The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. The compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. The compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product.Type: GrantFiled: July 24, 2007Date of Patent: July 31, 2012Assignee: Sandoz AGInventors: Christian Welz, Gottfried Stubauer, Andreas Schmarda, Herwig Jennewein, Ingolf Macher, Johannes Ludescher
-
Publication number: 20120190613Abstract: The invention features echinocandin class compounds that have been modified to (i) have activity against one or more fungal species or genera; (ii) have increased aqueous solubility; (iii) have an increased therapeutic index; (iv) be suitable for topical administration; and/or (v) be suitable for oral administration. The echinocandin class compounds of the invention include, for example, a PEG, alkyl-PEG, aryl-PEG, alkaryl-PEG, PEG-alkyl, PEG-aryl, or PEG-alkaryl substituent.Type: ApplicationFiled: August 26, 2010Publication date: July 26, 2012Inventors: Kenneth Duke James, JR., Christopher Patrick Laudeman
-
Publication number: 20120157371Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: December 12, 2011Publication date: June 21, 2012Inventors: Chongxi YU, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
-
Publication number: 20120101030Abstract: The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.Type: ApplicationFiled: September 20, 2011Publication date: April 26, 2012Applicant: XELLIA PHARMACEUTICALS APSInventors: Swapnil Shirode, Piyush Patel, Suresh Gidwani, Neil Parikh, Atul Patil, Anita Bevetek Mocnik
-
Publication number: 20120088671Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSASInventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
-
Publication number: 20120040033Abstract: The current invention discloses drug formulations of anti-infective mangrove extracts and their ability to block the reproductive capabilities of viruses, funguses, bacteria and tumors. Mangrove extracts can be ingested internally to prevent the proliferation of viruses, funguses, bacteria and tumors in humans and other animals; or the mangrove extracts can be applied directly to the skin, in the form of a disinfectant hand gel, to fight microbial infection.Type: ApplicationFiled: August 10, 2011Publication date: February 16, 2012Inventor: Ernest Timothy Armstrong
-
Publication number: 20110294724Abstract: Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N?2.Type: ApplicationFiled: March 29, 2011Publication date: December 1, 2011Inventors: Jya-Wei CHENG, Kuo-Chun HUANG, His-Tsu CHENG, Hui-Yuan YU
-
Publication number: 20110281788Abstract: The present invention relates to the treatment of fungal infections and provides compounds, compositions, methods and for treating the same.Type: ApplicationFiled: September 17, 2009Publication date: November 17, 2011Inventors: Peter John Coote, Mark Harris
-
Publication number: 20110136729Abstract: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.Type: ApplicationFiled: May 25, 2010Publication date: June 9, 2011Inventors: Shien Lu, James L. Smith, Frank Austin, Ganyu Gu
-
Publication number: 20110105387Abstract: The invention comprises a method of treatment using an oral capsule dose of rapamycin formulated with PEG-lipids. Two types of PEG-lipids are used in the formulation. A solubilizing agent dissolves the rapamycin, and solidifying agent is used to convert the solution of rapamycin/solubilizing agent to a more solid form.Type: ApplicationFiled: September 18, 2010Publication date: May 5, 2011Inventors: Nian Wu, Brian Charles Keller
-
Publication number: 20110104262Abstract: There is provided a pharmaceutical composition comprising an antimycotic agent and an antiviral agent, useful for prophylaxis and/or treatment of an associated infection and/or disease and a method of manufacturing thereof.Type: ApplicationFiled: April 16, 2009Publication date: May 5, 2011Applicant: CIPLA LIMITEDInventors: Amar Lulla, Geena Malhotra
-
Publication number: 20110020216Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.Type: ApplicationFiled: June 11, 2008Publication date: January 27, 2011Inventors: David James Mooney, Omar abdel-Rahman Ali
-
Publication number: 20110015121Abstract: A compound useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, is provided. A fungus Acremonium persicinum was collected, and cyclic compounds were isolated from culture liquids thereof. The present inventors confirmed that the cyclic compounds or salts thereof have a potent antifungal activity and are useful as medicaments, particularly an antifungal agent, and thus the present invention was completed. The cyclic compound and the salt thereof according to the present invention can be used as an agent for preventing or treating mycoses, particularly deep-seated mycoses.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Inventors: Ikuko Nakamura, Koji Yoshikawa, Keisuke Ohsumi, Ryuichi Kanasaki, Shigehiro Takase
-
Publication number: 20100279861Abstract: Novel isoxazolidinone compounds useful in the treatment and/or prevention of human and animal fungal infections, as well as in the control of phytopathogenic fungi in crops are described. Two novel strains of fungi, ATCC No. PAT-7894 and ATCC No. PAT-7895, are disclosed for the preparation of the described isoxazolidinone compounds.Type: ApplicationFiled: August 12, 2008Publication date: November 4, 2010Inventors: Gerald F Bills, Javier Collado, Craig A. Parish, Fernando Pelaez, Gonzalo Platas, Terry Roemer